title: Thrombolysis in recurrent lacunar stroke: a case example.
abstract: OBJECTIVE
  We report a case of intravenous thrombolysis in a patient with early recurrent stroke. A 62-year-old man recovered nearly completely after a lacunar infarct of the left putamen. He suffered stroke recurrence 7 days later due to a new infarct in the left internal capsule. Intravenous alteplase 0.9 mg/kg was administered 40 min after the symptom onset resulting in significant neurologic improvement.
  
  
  CONCLUSIONS
  Intravenous thrombolysis may be safe for early recurrent lacunar stroke in patients with relatively small risk of hemorrhage.
authors.affiliation: Department of Neurology, People Hospital, Vietnam. dr_nguyenhuythang@yahoo.com
authors.forename: T H
authors.initials: TH
authors.lastname: Nguyen
authors.forename: D
authors.initials: D
authors.lastname: Vo
authors.forename: M B
authors.initials: MB
authors.lastname: Ngo
authors.forename: A L T
authors.initials: AL
authors.lastname: Truong
authors.forename: C Q
authors.initials: CQ
authors.lastname: Bui
authors.forename: L K
authors.initials: LK
authors.lastname: Nguyen
authors.forename: T V
authors.initials: TV
authors.lastname: Le
mesh_terms: D020520:Brain Infarction / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D002545:Brain Ischemia / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D016893:Carotid Stenosis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology; D018450:Disease Progression; D004632:Emergency Medical Services / Q000379:methods / Q000592:standards; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006801:Humans; D020772:Internal Capsule / Q000187:drug effects* / Q000473:pathology; D018810:Magnetic Resonance Angiography; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D020768:Middle Cerebral Artery / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D010291:Paresis / Q000209:etiology / Q000503:physiopathology; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011699:Putamen / Q000098:blood supply / Q000187:drug effects / Q000473:pathology; D055502:Secondary Prevention; D015912:Thrombolytic Therapy / Q000379:methods*; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D010959:Tissue Plasminogen Activator